New Thrombotic Events in Ischemic Stroke Patients with Elevated Factor VIII. (16th December 2014)

• Record Type: Journal Article
• Authors: Gouse, Brittany M.; Boehme, Amelia K.; Monlezun, Dominique J.; Siegler, James E.; George, Alex J.; Brag, Katherine; Albright, Karen C.; Beasley, T. Mark; Leissinger, Cindy; El Khoury, Ramy; Martin-Schild, Sheryl
• Other Names: Prisco Domenico Academic Editor.
• Is Part Of: Thrombosis. Volume 2014(2014)
• Publication Date: 2014-12-16
• Subjects: Thrombosis -- Periodicals; Thrombosis; Thrombosis; Electronic journals; Periodical; Electronic journals; Periodicals; 616.135
• DOI: 10.1155/2014/302861
• Languages: English
• ISSNs: 2090-1488

Abstract

Abstract : Background . Heightened levels of Factor VIII (FVIII) have been associated with both arterial and venous thrombosis. While elevated FVIII is common during acute ischemic stroke (AIS), whether elevated FVIII confers an increased risk for recurrent thrombotic events (RTEs) following AIS has not been previously explored. Methods . Consecutive AIS patients who presented to our center between July 2008 and September 2013 and had FVIII measured during admission were identified from our stroke registry. Baseline characteristics and the occurrence of RTE (recurrent or progressive ischemic stroke, DVT/PE, and MI) were compared in patients with and without elevated FVIII levels. Results . Of the 298 patients included, 203 (68.1%) had elevated FVIII levels. Patients with elevated FVIII had higher rates of any in-hospital RTE (18.7% versus 8.4%, P = 0.0218 ). This association remained after adjustment for baseline stroke severity and etiology (OR 1.01, 95% CI 1.00–1.01, P = 0.0013 ). Rates of major disability were also higher in patients who experienced a RTE (17.8% versus 3.2%, P < 0.0001 ). Conclusion . A significantly higher frequency of in-hospital RTEs occurred in AIS patients with elevated FVIII. The occurrence of such events was associated with higher morbidity. Further study is indicated to evaluate whether FVIII is a candidate biomarker for increased risk of RTEs following AIS.